Literature DB >> 28057800

Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase.

Cheryl Allen1, Sandhya Kortagere1, Huaxiang Tong1, Robert A Matthiesen1, Joseph I Metzger1, David F Wiemer1, Sarah A Holstein2.   

Abstract

The isoprenoid donor for protein geranylgeranylation reactions, geranylgeranyl diphosphate (GGDP), is the product of the enzyme GGDP synthase (GGDPS) that condenses farnesyl diphosphate (FDP) and isopentenyl pyrophosphate. GGDPS inhibition is of interest from a therapeutic perspective for multiple myeloma because we have shown that targeting Rab GTPase geranylgeranylation impairs monoclonal protein trafficking, leading to endoplasmic reticulum stress and apoptosis. We reported a series of triazole bisphosphonate GGDPS inhibitors, of which the most potent was a 3:1 mixture of homogeranyl (HG) and homoneryl (HN) isomers. Here we determined the activity of the individual olefin isomers. Enzymatic and cellular assays revealed that although HN is approximately threefold more potent than HG, HN is not more potent than the original mixture. Studies in which cells were treated with varying concentrations of each isomer alone and in different combinations revealed that the two isomers potentiate the induced-inhibition of protein geranylgeranylation when used in a 3:1 HG:HN combination. A synergistic interaction was observed between the two isomers in the GGDPS enzyme assay. These results suggested that the two isomers bind simultaneously to the enzyme but within different domains. Computational modeling studies revealed that HN is preferred at the FDP site, that HG is preferred at the GGDP site, and that both isomers may bind to the enzyme simultaneously. These studies are the first to report a set of olefin isomers that synergistically inhibit GGDPS, thus establishing a new paradigm for the future development of GGDPS inhibitors.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28057800      PMCID: PMC5325083          DOI: 10.1124/mol.116.107326

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

1.  Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

Authors:  F P Coxon; M H Helfrich; R Van't Hof; S Sebti; S H Ralston; A Hamilton; M J Rogers
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

Review 2.  Geranylgeranyl diphosphate synthase: an emerging therapeutic target.

Authors:  A J Wiemer; D F Wiemer; R J Hohl
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

Review 3.  Is there a future for prenyltransferase inhibitors in cancer therapy?

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Curr Opin Pharmacol       Date:  2012-07-18       Impact factor: 5.547

4.  Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates.

Authors:  Robert A Matthiesen; Veronica S Wills; Joseph I Metzger; Sarah A Holstein; David F Wiemer
Journal:  J Org Chem       Date:  2016-09-20       Impact factor: 4.354

5.  Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells.

Authors:  Huaxiang Tong; Sarah A Holstein; Raymond J Hohl
Journal:  Anal Biochem       Date:  2005-01-01       Impact factor: 3.365

6.  Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.

Authors:  M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

7.  Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

Authors:  S P Luckman; F P Coxon; F H Ebetino; R G Russell; M J Rogers
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

8.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

Authors:  A Thibault; D Samid; A C Tompkins; W D Figg; M R Cooper; R J Hohl; J Trepel; B Liang; N Patronas; D J Venzon; E Reed; C E Myers
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

9.  Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase.

Authors:  Xiang Zhou; Jacqueline E Reilly; Kathleen A Loerch; Raymond J Hohl; David F Wiemer
Journal:  Beilstein J Org Chem       Date:  2014-07-18       Impact factor: 2.883

10.  Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Authors:  Kaitlyn M Dykstra; Cheryl Allen; Ella J Born; Huaxiang Tong; Sarah A Holstein
Journal:  Oncotarget       Date:  2015-12-08
View more
  11 in total

1.  In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.

Authors:  Staci L Haney; Yashpal S Chhonker; Michelle L Varney; Geoffrey Talmon; Lynette M Smith; Daryl J Murry; Sarah A Holstein
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

2.  Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.

Authors:  Staci L Haney; Yashpal S Chhonker; Michelle L Varney; Geoffrey Talmon; Daryl J Murry; Sarah A Holstein
Journal:  Invest New Drugs       Date:  2018-03-02       Impact factor: 3.850

Review 3.  Targeting prenylation inhibition through the mevalonate pathway.

Authors:  Pimyupa Manaswiyoungkul; Elvin D de Araujo; Patrick T Gunning
Journal:  RSC Med Chem       Date:  2019-12-23

4.  Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.

Authors:  Veronica S Wills; Joseph I Metzger; Cheryl Allen; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2017-03-04       Impact factor: 3.641

5.  Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors.

Authors:  Daniel B Goetz; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2020-06-30       Impact factor: 3.641

6.  Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application.

Authors:  Yashpal S Chhonker; Staci L Haney; Robert A Matthiesen; David F Wiemer; Sarah A Holstein; Daryl J Murry
Journal:  J Pharm Biomed Anal       Date:  2018-02-06       Impact factor: 3.935

7.  α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.

Authors:  Robert A Matthiesen; Michelle L Varney; Pauline C Xu; Alex S Rier; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2017-10-19       Impact factor: 3.641

8.  In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.

Authors:  Staci L Haney; Michelle L Varney; Yashpal Chhonker; Geoffrey Talmon; Lynette M Smith; Daryl J Murry; Sarah A Holstein
Journal:  Pharmacol Res       Date:  2021-03-03       Impact factor: 7.658

Review 9.  Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.

Authors:  Staci L Haney; Veronica S Wills; David F Wiemer; Sarah A Holstein
Journal:  Molecules       Date:  2017-05-27       Impact factor: 4.411

10.  Impact of α-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.

Authors:  Alisa E R Fairweather; Daniel B Goetz; Chloe M Schroeder; Nazmul H Bhuiyan; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2021-07-11       Impact factor: 3.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.